EYA4 and cancer: Either bortezomib or MG132 treatment robustly increased the steady-levels of EYA4 protein―the phenomenon that could also be observed in pancreatic patient-derived cancer cells (PDC), EYA4-proficient T3M-4 (T-4) PDAC cells and the non-tumorigenic human pancreatic ductal epithelial (HPDE) cells (Figure 1A and Supplemental Figure 1A-D), indicating that the posttranslational degradation of EYA4 protein by UPS is a common feature not restricted to PDAC cells.